BfR (German Federal Institute for Risk Assessment)

In this guide

In this guide

- 1. Background and Introduction Garcinia cambogia oral consumption
- 2. Data from authoritative bodies Garcinia cambogia oral consumption
- 3. Chemical composition Garcinia cambogia oral consumption
- 4. ANSES Garcinia cambogia oral consumption
- 5. AESAN Garcinia cambogia oral consumption
- 6. Australian TGA Garcinia cambogia oral consumption
- 7. <u>BfR (German Federal Institute for Risk Assessment) Garcinia cambogia oral</u> consumption
- 8. EFSA Garcinia cambogia oral consumption
- 9. Health Canada Garcinia cambogia oral consumption
- 10. NCCIH Garcinia cambogia oral consumption
- 11. Data from literature search Garcinia cambogia oral consumption
- 12. Human data Garcinia cambogia oral consumption
- 13. Hepatotoxic case reports Garcinia cambogia oral consumption
- 14. Animal studies Garcinia cambogia oral consumption
- 15. Exposure Garcinia cambogia oral consumption
- 16. Uncertainties Garcinia cambogia oral consumption
- 17. Risk Characterisation Garcinia cambogia oral consumption
- 18. Questions to the Committee Garcinia cambogia oral consumption
- 19. Abbreviations Garcinia cambogia oral consumption
- 20. References Garcinia cambogia oral consumption

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

101. Although not an official published risk assessment, a slide deck on "Risk Assessment Approaches and Methodology – an Overview" presented HCA

from *G. cambogia* extracts as a case study - is publicly available (Hirsch-Ernst, 2022). In this, it was noted that doses via supplements was up to 3,000 mg HCA/day.

Three animal studies (oral administration, rats) were summarised (see Figure 3). It was observed that at high doses male rats showed signs of testicular toxicity and/or impaired spermatogenesis (i.e. sperm quality and sperm count).

Figure 3 – Animal studies as summarised in Hirsch-Ernst, (2022) (reproduced from Hirsch-Ernst, 2022).

Study	preparation tested	Results
90-day	Garcinia c. extract (41,2% HCA)	Testicular atrophies, germ cell degeneration, impaired spermatogenesis LOAEL: 778 mg HCA/kg bw; NOAEL: 389 mg HCA/kg bw
90-day	Ca ²⁺ /K*-HCA (60% HCA)	No testicular toxicity reported; hematology, clinical chemistry, histopathology without changes NOAEL: 1500 mg HCA/kg bw
Reprod. toxicity	Ca ² */K*-HCA (60% HCA)	No effects on the reproductive system of \Im / φ animals observed; sperm quality & reproductive parameters of \Im animals not affected NOAEL(\Im): 611 mg HCA/kg bw (= highest tested dose)

This figure shows a table summarising 3 animal studies as summarised in Hirsch-Ernst, (2022) (reproduced from Hirsch-Ernst, 2022).

- 103. In human intervention studies that assessed the safety of HCA intake, the observed adverse effects were mostly non-specific and were in similar occurrence as in control groups. The parameters of potential effects on spermatogenesis were not investigated.
- The risk assessment was as follows. It was unclear whether the reproductive toxicological effects observed in male rats were due to the possible impurities in the extracts or were compound-specific to high doses of HCA intake. The lowest no-observed adverse effect level (NOAEL) was determined to be 389 mg HCA/kg bw per day (*G. cambogia* extract, 41.2% HCA). The human data were found to be inadequate with regards to considerations for the male reproductive system. The lack of specifications for HCA preparations/*G. cambogia* extracts added to food supplements was noted, and as such "transferability" of the above NOAEL to other preparations of food supplements may not be appropriate. Lastly, uncertainties regarding the health assessment of prolonged HCA intakes, especially at high doses (3,000 mg HCA/day) were noted.